Halozyme announces expansion of global collaboration with argenx

Halozyme Therapeutics (HALO) announced that argenx (ARGX) has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE for a total of six targets, including for the neonatal Fc receptor target. VYVGART Hytrulo, argenx’s branded FcRn blocker, is approved by the U.S. Food and Drug Administration for chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis, with additional approvals granted in greater than25 countries globally for the latter indication. Under the terms of the expanded exclusive agreement, argenx will make upfront payments of $7.5 million per target nomination for a total of $30 million to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment of up to $85 million per nominated target.